These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 19077094)

  • 1. Complete remission of psoriasis following bevacizumab therapy for colon cancer.
    Akman A; Yilmaz E; Mutlu H; Ozdogan M
    Clin Exp Dermatol; 2009 Jul; 34(5):e202-4. PubMed ID: 19077094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy.
    August DA; Serrano D; Poplin E
    J Surg Oncol; 2008 Feb; 97(2):180-5. PubMed ID: 18095268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidental reduction in the size of liver hemangioma following use of VEGF inhibitor bevacizumab.
    Mahajan D; Miller C; Hirose K; McCullough A; Yerian L
    J Hepatol; 2008 Nov; 49(5):867-70. PubMed ID: 18814928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anti-VEGF therapy with bevacizumab in breast cancer].
    Tóth J; Gonda A; Szántó J
    Lege Artis Med; 2008 Oct; 18(10):669-73. PubMed ID: 19227609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells.
    Calvani M; Trisciuoglio D; Bergamaschi C; Shoemaker RH; Melillo G
    Cancer Res; 2008 Jan; 68(1):285-91. PubMed ID: 18172321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
    Marty M; Pivot X
    Eur J Cancer; 2008 May; 44(7):912-20. PubMed ID: 18396037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab in the treatment of breast cancer.
    Koutras AK; Fountzilas G; Makatsoris T; Peroukides S; Kalofonos HP
    Cancer Treat Rev; 2010 Feb; 36(1):75-82. PubMed ID: 19932567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caution in adding bevacizumab in the adjuvant treatment of breast cancer.
    Ziogas D; Roukos D
    Ann Surg Oncol; 2010 Feb; 17(2):653-4; author reply 655-6. PubMed ID: 19888632
    [No Abstract]   [Full Text] [Related]  

  • 9. Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis--a possible target for novel therapies?
    Canavese M; Altruda F; Ruzicka T; Schauber J
    J Dermatol Sci; 2010 Jun; 58(3):171-6. PubMed ID: 20430590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility of anti-VEGF agent bevacizumab in patients with Crohn's disease.
    Coriat R; Mir O; Leblanc S; Ropert S; Brezault C; Chaussade S; Goldwasser F
    Inflamm Bowel Dis; 2011 Jul; 17(7):1632. PubMed ID: 21674721
    [No Abstract]   [Full Text] [Related]  

  • 11. Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels.
    Brostjan C; Gebhardt K; Gruenberger B; Steinrueck V; Zommer H; Freudenthaler H; Roka S; Gruenberger T
    Clin Cancer Res; 2008 Apr; 14(7):2065-74. PubMed ID: 18381946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigational VEGF antagonists for psoriasis.
    Crawshaw AA; Griffiths CE; Young HS
    Expert Opin Investig Drugs; 2012 Jan; 21(1):33-43. PubMed ID: 22088218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions.
    Wada J; Suzuki H; Fuchino R; Yamasaki A; Nagai S; Yanai K; Koga K; Nakamura M; Tanaka M; Morisaki T; Katano M
    Anticancer Res; 2009 Mar; 29(3):881-8. PubMed ID: 19414323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of melanoma-associated neoangiogenesis by bevacizumab.
    Jaissle GB; Ulmer A; Henke-Fahle S; Fierlbeck G; Bartz-Schmidt KU; Szurman P
    Arch Dermatol; 2008 Apr; 144(4):525-7. PubMed ID: 18427047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab in the treatment of ovarian cancer.
    Han ES; Monk BJ
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor inhibitors in colon cancer.
    Díaz-Rubio E
    Adv Exp Med Biol; 2006; 587():251-75. PubMed ID: 17163170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug insight: antiangiogenic therapies for gastrointestinal cancers--focus on monoclonal antibodies.
    Reinacher-Schick A; Pohl M; Schmiegel W
    Nat Clin Pract Gastroenterol Hepatol; 2008 May; 5(5):250-67. PubMed ID: 18382435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
    Chase JL
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.
    Ferrara N; Hillan KJ; Gerber HP; Novotny W
    Nat Rev Drug Discov; 2004 May; 3(5):391-400. PubMed ID: 15136787
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
    Grothey A; Ellis LM
    Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.